The stock's market cap is $308.31 million.
For Sangamo, the deal gives the small biotech more flexibility as far its resources as well as validating its gene technology platform.
Opko Health Inc. (NASDAQ:OPK) have shown a low EPS growth of -7.60% in the last 5 years and has earnings growth of -927.40% yoy. Altrinsic Global Advisors LLC raised its position in shares of Sangamo Therapeutics by 26.0% in the third quarter. The company presently has a consensus rating of "Hold" and a consensus target price of $7.75. This calculation is derived by dividing the current share price by the projected earnings per share.
For this year, Penumbra Inc (NYSE:PEN) is performing 40.2%.
A 52-week high/low is the highest and lowest price that a stock has traded at during the previous year. The last close places the company's stock about $0.05 off its 52 week high of $89.5 and $43.57 above the 52 week low of $45.88.
Sangamo Therapeutics, Inc. and Pfizer Inc. today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter. Current price level places the company's stock about -42.76% from the 52-week high and 64.15% away from the 52-week low. During the same period past year, the firm posted ($0.23) earnings per share. Mean recommendation on this stock is 2.90. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target.
Sangamo Therapeutics Inc (NASDAQ:SGMO) was the recipient of a large growth in short interest during the month of April.
Mattis makes clear United States commitment to protecting Turkey
Mattis acknowledged Turkey's concerns that weapons could end up in the hands of the Kurdish militants in Turkey, known as the PKK. Spokesman Redur Khalil called on Ankara to let go of its "unjustified" fears of the group.
Let's take a look at how the stock has been performing recently.
Regions Financial Corp (NYSE:RF)'s shares are trading at $14.28 with decline of -0.45%. The current price change puts the market capitalization at $305.46 mln. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. Also, the Hold rating count is 2 as of 05/10/17.
The Stock had a 1.67 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.8 and 1.67 respectively. Its share price has grown 20.83% in three months and is down -3.33% for the last five trades.
Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise.
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company.
While looking at the Stock's Performance, Sangamo Biosciences Inc. now shows a Weekly Performance of 52.17%, where Monthly Performance is 62.79%, Quarterly performance is 86.67%, 6 Months performance is 108.96% and yearly performance percentage is 16.28%. The stock, after opening at $4.65, hit $4.55 through the close by scoring -1.09%. Year to Date performance value (YTD perf) value is 129.51%.
Comments